Global Antibody-Drug Conjugates (ADC) Market Research Report 2022: Two ADCs Are Already on the Market, Such as Brentuximab Vedotin and Trastuzumab Emtansine – Forecast to 2028 –


DUBLIN–(BUSINESS WIRE)–The report “Global Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Regional Outlook and Forecast, 2022-2028” has been added to the report from offer.

The global market size of antibody-drug conjugates is expected to reach USD 13.8 billion by 2028, growing the market at 14.2% CAGR during the forecast period.

Antibody-drug conjugates (ADCs) are particularly effective biopharmaceutical drugs in the treatment of cancer. ADCs are designed to kill cancer cells while leaving healthy cells alone. Antibody-drug conjugates (ADCs) are a new class of cancer drugs that have been created in recent years.

ADCs have been shown to be a good substitute for conventional cancer treatments like chemotherapy or combination therapy due to their low off-target effects and high cytotoxicity at tumor sites. Several advances in antibody-drug engineering have resulted in highly effective tumor-targeting drugs with a broad therapeutic window.

Two ADCs are already on the market such as Brentuximab vedotin and Trastuzumab emtansine, and many more are in clinical development. Enzymes in conjunction with prodrugs have proven to be a viable option. Horseradish peroxidase (HRP), a glyco-enzyme, has been shown to convert the hormone indole-3-acetic acid (IAA) into a highly effective cytotoxic poison.

The use of this mixture of IAA and HRP in techniques such as gene-directed enzyme prodrug therapy (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT) has been investigated (ADEPT).

For example, the market is predicted to rise owing to increased investment in this industry by key players such as Pfizer Inc., Piramal Pharma Solution, F. Hoffman La-Roche, and Seagen, for the development of new ADCs for the treatment cancer.

Additionally, for example, to meet increased demand for commercial ADCs in the UK, CDMO Piramal Pharma Solutions (PPS) has committed USD 74.4 million for the formation of two modern antibody-drug conjugate production facilities ( ADC) to its current sites in Grangemouth, Scotland in February 2022.

Clinical trials are conducted by most companies to bring new products to market and to expand labeling of products that have already been approved. Seagen, for example, began Phase 1 clinical trials of two new antibody-drug conjugates, SGN-B7H4V and SGN-PDL1V, in patients with advanced solid cancers in January 2022.

Additionally, the company, in collaboration with Astellas, has completed patient recruitment for the EV-103 K cohort trial, which is used to treat first-line metastatic urothelial cancer (mUC). Market expansion is expected to be fueled by satisfactory completion of clinical trial research and future product approval.

COVID-19 Impact Analysis

With the global COVID-19 pandemic, the expansion of many industries saw a drop in demand, however, several other areas remained untouched and showed promising indicators of future growth.

COVID-19 has impacted several businesses in different ways. While activities in hospitals and healthcare facilities were severely restricted due to social distancing and confinement measures adopted by governments around the world, the outbreak of the COVID-19 pandemic had a massive impact on the activity of antibody-drug conjugates.

Market Growth Factors

The increase in cancer cases

Rising incidence of cancer among the population is a serious disease that occurs due to various unknown reasons, which has raised a substantial need for advanced medical equipment to treat and cure various types of cancer diseases.

The supporting equipment is widely used in companion diagnostics, personalized pharmaceuticals and other disease diagnostics, such as disease risk assessment and drug research and development. The increasing use of biomarkers in the detection of diseases is one of the major factors predicted to enhance the growth of the Antibody-Drug Conjugates market in the coming years. Lung and breast cancer are more existing cancers recorded in recent years.

Growing Health Spending in Developing Countries

Governments in emerging countries are increasing spending in the health sector. Governments around the world plan to improve their healthcare systems with this investment to provide better and more modern solutions and minimize cases of chronic diseases.

An aging population, growing middle class, rising proportion of lifestyle-related diseases, increased focus on public-private partnerships, accelerated adoption of digital technologies including telemedicine, as well as increased investor interest and FDI inflows over the past two decades are all spurring the growth of health care infrastructure.

Marketing Restriction Factor:

Higher cost in cancer treatment

The exorbitant cost of cancer treatment is the most critical challenge facing the antibody-drug conjugates market. Cancer drug prices are rising as their success rates improve. Cancer drugs can be expensive on a monthly basis, which most people cannot afford.

Even the rich, the poor or the middle classes, struggle to bear the price of such expensive therapies. The cost of drugs can be many times what many people earn in a month. Rising price of cancer diagnosis and treatment in poor countries is another major impediment to market growth.

Patients are increasingly choosing a variety of low-cost detection techniques, which limits the number of patients screened for the purpose.

Approvals and tests:

  • August 2021: GlaxoSmithKline has received approval from the United States Food and Drug Administration (FDA) for a new indication for JEMPERLI (dostarlimab-gxly), an antibody that blocks programmed cell death receptor 1 (PD-1). This approval was intended to provide treatment to adult patients with repetitive or advanced solid tumors deficient in mismatch repair (dMMR), as evidenced by an FDA-approved test, who progressed during or after treatment and who do not has no satisfactory alternative treatment options.

  • September 2021: Astellas Pharma and Seagen received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for PADCEV (enfortumab vedotin). This approval was for radically unresectable urothelial carcinoma that progressed after cancer chemotherapy.

  • Apr-2021: ADC Therapeutics has received U.S. Food and Drug Administration (FDA) approval for ADC Therapeutics’ ZYNLONTA as a third-line treatment for patients with diffuse large B-cell lymphoma (LDGCB) relapsed or refractory (r/r). This approval was intended to include patients with DLBCL developing from high-grade B-cell lymphoma and low-grade lymphoma.

Company Profiles

  • Takeda Pharmaceutical Company Limited

  • F. Hoffmann-La Roche Ltd.

  • AstraZeneca PLC

  • GlaxoSmithKline PLC

  • Pfizer, Inc.

  • Astellas Pharma, Inc.

  • Gilead Sciences, Inc.

  • Seagen, Inc.

  • ADC Therapeutics SA

  • Daiichi Sankyo Company, Limited

Scope of the study

By app

  • Breast cancer

  • Leukemia

  • Urothelial cancer and bladder cancer

  • Others

By technology

  • Cleavable linker

  • Non-cleavable linker

  • Others

By geography

  • North America

  • WE

  • Canada

  • Mexico

  • Rest of North America

  • Europe

  • Germany

  • UK

  • France

  • Russia

  • Spain

  • Italy

  • The rest of Europe

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Rest of Asia-Pacific


  • Brazil

  • Argentina

  • United Arab Emirates

  • Saudi Arabia

  • South Africa

  • Nigeria

  • Rest of LAMEA

For more information about this report visit


Comments are closed.